05 May 2017

NetScientific Portfolio Company ProAxsis Presents New Data Further Validating ProteaseTag® Technology at Major US

 

London, UK – 05 May 2017 – NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that its portfolio company, ProAxsis, will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society (ATS) Conference, which takes place between May 19th-24th in Washington DC.

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. ATS has accepted abstracts for the presentation of data on three products being developed by ProAxsis in chronic diseases including COPD, bronchiectasis and Cystic Fibrosis at the conference.

“The broad range of major disease indications covered in these studies demonstrates the versatility of the ProteaseTag® technology being developed by ProAxsis. We look forward to the continued development of these exciting products and expect to see them commercially available by the end of 2017.”

François R. Martelet

Chief Executive Officer of NetScientific and Chairman of ProAxsis

The full text of the announcement issued by ProAxsis follows:

ProAxsis abstracts at 2017 American Thoracic Society Conference

Date: May 4, 2017

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes place between May 19th-24th in Washington DC. The company has had three abstracts accepted for presentation by the conference review committee, details of which are below:

The Development of Novel ProteaseTags® for the Capture and Disclosure of Mast Cell Tryptase A34-CLINICAL AND CELLULAR STUDIES IN ALLERGIC DISEASE Thematic Poster Session (presenting author Dr Timothy Ferguson) SUNDAY, MAY 21, 2017 9:15 AM-4:15 PM

The Development of a Novel ProteaseTag® Immunoassay for the Detection and Quantification of Active Plasmin C78-FIBROSIS: MEDIATORS AND MODULATORS Thematic Poster Session (presenting author Dr Darragh McCafferty) TUESDAY, MAY 23, 2017 9:15 AM-4:15 PM

Development of NEATstik® - a Novel Lateral Flow Device for the Detection of Active Neutrophil Elastase in Patients with Respiratory Disease C74-ADVANCES IN TRANSLATIONAL COPD Thematic Poster Session (presenting author Dr Kelly Moffitt) TUESDAY, MAY 23, 2017 9:15 AM-4:15 PM

Dr David Ribeiro, CEO of ProAxsis, said: “What I find most exciting about the work we’re presenting at this year’s ATS Conference is the variety. We’re providing data on three of our R&D products, all of which are expected to launch before the end of 2017. Our first point-of-care test, NEATstik®, has the potential to re-invent how the risk of future exacerbations for patients with long-term chronic diseases such as COPD, bronchiectasis and CF, is monitored. We expect the active plasmin immunoassay to act as a biomarker of fibrosis in diseases such as IPF, and our tryptase assay should provide quantification of mast cell involvement in diseases such as asthma and COPD. We’re very grateful to Invest Northern Ireland, who have supported our development work on these two target proteases.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

For more information, please contact:

NetScientific
François R. Martelet, M.D., CEO Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800

Stifel Nicolaus Europe Limited (NOMAD and broker)
Jonathan Senior/ David Arch/ Ben Maddison
Tel: +44 (0)20 7710 7600

Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com

About NetScientific Plc

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net


Back to previous page